JANX vs MSFT: Which Stock is Better?
Side-by-side comparison of Janux Therapeutics Inc and Microsoft Corp in 2026
JANX
Janux Therapeutics Inc
$15.04
MSFT
Microsoft Corp
$415.05
Key Metrics Comparison
| Metric | JANX | MSFT | Winner |
|---|---|---|---|
| Market Cap | $906.39M | N/A | JANX |
| P/E Ratio | N/A | 24.57 | MSFT |
| EPS (TTM) | $N/A | $16.00 | MSFT |
| Revenue Growth | 21.8% | 0.2% | JANX |
| Gross Margin | -1159.0% | 68.6% | MSFT |
Analyze JANX
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is JANX or MSFT a better investment?
Comparing JANX and MSFT: Janux Therapeutics Inc has a market cap of $906.39M while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between JANX and MSFT?
JANX (Janux Therapeutics Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: JANX or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: JANX or MSFT?
JANX has higher revenue growth at 21.8% vs 0.2% for MSFT.
Which company is more profitable: JANX or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to -1159.0% for JANX.
Which is the larger company: JANX or MSFT?
Janux Therapeutics Inc (JANX) is larger with a market cap of $906.39M compared to N/A for MSFT.
Should I buy JANX or MSFT in 2026?
Both JANX and MSFT have investment merit. JANX trades at $15.04 while MSFT trades at $415.05. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between JANX and MSFT stock?
Key differences: Market Cap ($906.39M vs N/A), P/E Ratio (N/A vs 24.6x), Revenue Growth (21.8% vs 0.2%), Gross Margin (-1159.0% vs 68.6%).